2016-08-242016-08-242008-04-29http://hdl.handle.net/10919/72583A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to the Brucella species is identified by detecting a genetic sequence for carboxyl-terminal (i.e. tail-specific) protease activity in a biological sample.application/pdfen-USPatenthttp://pimg-fpiw.uspto.gov/fdd/45/647/073/0.pdf11246957424/252.1435/471435/477A61K39/099A61K2039/522C12Q1/689C12N1/36C12N9/527364745